A study from global pharmaceutical company Galderma has indicated that 95% of patients treated with Azzalure abobotulinum toxin A achieved high levels of satisfaction with two treatments per year.
The research was conducted under the US brand name Dysport and featured 120 patients aged 18-65 with moderate to severe glabellar lines at maximum frown. It also found that 97% of patients thought the treatment result looked natural.
Other results indicated that 84% of patients were satisfied/very satisfied with the aesthetic outcome in the treated area at 12 months, 98% of patients would like to receive the same treatment again at 12 months, and 97% of patients would recommend the treatment to friends and family. One patient experienced an adverse event of mild injection-site bruising.
Board-certified dermatologist Dr Joel Cohen, who was an investigator for the study, said, “These top-line results suggest that aesthetic specialists can feel confident administering injections that match patient goals of treatment efficacy from every three to four months to a twice-yearly schedule.”
